Clearside Biomedical (NASDAQ: CLSD) is one of 305 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Clearside Biomedical to related companies based on the strength of its analyst recommendations, profitability, institutional ownership, dividends, earnings, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Clearside Biomedical and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearside Biomedical 0 0 5 0 3.00
Clearside Biomedical Competitors 772 3089 11320 227 2.71

Clearside Biomedical currently has a consensus target price of $20.00, indicating a potential upside of 187.77%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.74%. Given Clearside Biomedical’s stronger consensus rating and higher probable upside, analysts plainly believe Clearside Biomedical is more favorable than its peers.


This table compares Clearside Biomedical and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Clearside Biomedical -27,225.52% -65.78% -53.90%
Clearside Biomedical Competitors -5,372.33% -434.01% -41.48%

Volatility and Risk

Clearside Biomedical has a beta of -11.76, suggesting that its stock price is 1,276% less volatile than the S&P 500. Comparatively, Clearside Biomedical’s peers have a beta of 6.35, suggesting that their average stock price is 535% more volatile than the S&P 500.

Earnings & Valuation

This table compares Clearside Biomedical and its peers revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Clearside Biomedical $520,000.00 -$25.88 million -4.14
Clearside Biomedical Competitors $290.00 million $35.57 million 165.49

Clearside Biomedical’s peers have higher revenue and earnings than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

52.5% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 20.9% of Clearside Biomedical shares are owned by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.